Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

June 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

June 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

June 19th 2013

Episode 6 - Recommended Guidelines and Payer Challenges

June 19th 2013

Episode 5 - Recent Additions to the Pipeline

June 19th 2013

Episode 4 - Pushing Reform through Immunotherapy

June 19th 2013

Episode 3 - Managed Care Concerns and Treatment Accessibility

June 19th 2013

Episode 1 - The Advent of Cancer Immunotherapy: Addressing Unmet Needs

June 19th 2013

Episode 2 - Diverse Applications Amidst a Growing Pipeline

June 19th 2013

Tailor Treatment Plans to Improve Outcomes in Managing NSCLC

Katie Sullivan

June 19th 2013

Looking at Specialty Pharmaceutical Rejections

Dea Belazi, PharmD, MPH

June 18th 2013

Third-Party Validation of Observed Savings From an Oncology Pathways Program

Bruce A. Feinberg, DO Scott Milligan, PhD Joseph Cooper, BS Winston Wong, PharmD Daniel Winn, MD Neil Schneider, ASA, MAAA Sheamus Parkes, FSA, MAAA Jeffrey Scott, MD

June 18th 2013

I-SPY Trials Seek Effective New Drug Combinations Using Adaptive Trial Design

Ben Leach

June 18th 2013

Observation of Prostate Cancer Both Effective and Cost-Efficient

June 17th 2013

Tailored Cancer Treatment Plans May Be Latest Trend

June 14th 2013

Proton Therapy Treatment Centers in Risk-sharing Health Systems

Katie Sullivan

Hospital systems across the country are increasingly vying to establish some of the first treatment centers to provide proton beam therapy, a high-tech radiation treatment for cancer.

June 13th 2013

Supreme Court Rules: No Patents for Human Genes

June 10th 2013

Immunotherapy Cancer Drugs Are Breakthrough, But Cost Is An Issue

June 7th 2013

More Cancer Specialist Nurses To Improve Hospital Care

June 6th 2013

PSA Screening: New Round Of Guidelines Emphasizes Importance Of Weighing Harms And Benefits

June 5th 2013

Trends in Patient Chemo Care Add Strain to Medicare

June 3rd 2013

Dr. George Addresses Provider Issues Regarding Immunotherapies

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.

June 3rd 2013

Dr. Kolodziej Discusses Personalized Medicine in Oncology

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting.

June 3rd 2013

Penn Survey Finds Cancer Drug Shortages Affect Treatment, Research

Ongoing shortages of common oncology chemotherapies have compelled physicians to substitute more expensive drugs, delay or suspend clinical trials, or even skip doses of chemotherapy, according to survey results gathered by a team from the University of Pennsylvania.

June 2nd 2013

Dr. Kolodziej Discusses The Use of Novel Treatments in Combination Therapy

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment.

June 2nd 2013

Dr. Andrew Seidman Discusses the Management of Patients With Brain Metastases

Over the 20 years I've been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress, said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.

June 2nd 2013

Phase III Study Finds Kidney-Cancer Drug Prevents Relapses of Ovarian Cancer

Ovarian cancer survivors could have an option for treatment after chemotherapy, based on the outcome of a phase III study of an approved oral therapy for kidney cancer and soft tissue sarcoma.

June 2nd 2013

In Phase II Study, Combination Therapy Extends Survival, Reduces Side Effects in Metastatic Melanoma Patients

Two-thirds of the metastatic myeloma patients in a phase II study were still alive a year after receiving a new combination therapy, compared to slightly more than half of patients receiving a standard monotherapy for the cancer, according to results presented today at the 49th Annual meeting of the American Society of Clinical Oncology in Chicago.

June 2nd 2013

Dr. George Talks About New Data on Checkpoint Inhibitors

In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013.

May 31st 2013

Long-Term Study Affirms Link Between Cardiovascular Fitness, Lower Cancer Risk in Men

This finding makes it clear that patients should be advised that they need to achieve a certain fitness level, and not just be told that they need to exercise. Unlike patient-reported exercise behavior, Lakoski said, fitness can be objectively and accurately measured in a clinical setting.

May 31st 2013

Results Show Idelalisib May Offer Option Where Few Exist for CLL Patients

Half the patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who were treated with idelalisib in a phase I study experienced rapid and prolonged tumor shrinkage, a promising finding given the limited treatment choices for this group.

May 30th 2013

Early Signs of Promise as Yale's Herbst Details PD-L1 Immunotherapy Data

Results detailed today offer hope that a new form of immunotherapy will propel the bodies of some cancer patients to fight tumors, not be overrun by them, according to a study outlined at the Annual Meeting of the American Society of Clinical Oncologists (ASCO) in Chicago.

May 30th 2013

Less is More: Researchers Surprised by Radiotherapy Results Involving Locally Advanced NSCLC

Patients in a phase III trial lived longer and experienced fewer treatment-related deaths from locally advanced non-small cell lung cancer (NSCLC) after receiving the standard dose of radiotherapy, compared to those receiving a high dose, according to a study presented today at the Annual Meeting of the American Society of Clinical Oncologists (ASCO).

...

173 174 175 176 177 178 179 180 181

...

186 >